[go: up one dir, main page]

MA45670A - Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome - Google Patents

Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome

Info

Publication number
MA45670A
MA45670A MA045670A MA45670A MA45670A MA 45670 A MA45670 A MA 45670A MA 045670 A MA045670 A MA 045670A MA 45670 A MA45670 A MA 45670A MA 45670 A MA45670 A MA 45670A
Authority
MA
Morocco
Prior art keywords
kits
compositions
processes
genome editing
editing efficiency
Prior art date
Application number
MA045670A
Other languages
English (en)
Inventor
Norzehan Abdul-Manan
David A Newsome
Jacque Zwahlen
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA45670A publication Critical patent/MA45670A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Document Processing Apparatus (AREA)
MA045670A 2016-07-13 2017-07-13 Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome MA45670A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662361781P 2016-07-13 2016-07-13
US201662361961P 2016-07-13 2016-07-13

Publications (1)

Publication Number Publication Date
MA45670A true MA45670A (fr) 2019-05-22

Family

ID=59388213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045670A MA45670A (fr) 2016-07-13 2017-07-13 Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome

Country Status (9)

Country Link
US (2) US11124805B2 (fr)
EP (2) EP4219462A1 (fr)
JP (1) JP7033583B2 (fr)
CN (1) CN109863143B (fr)
AU (2) AU2017295720B2 (fr)
CA (1) CA3030783A1 (fr)
ES (1) ES2938210T3 (fr)
MA (1) MA45670A (fr)
WO (1) WO2018013840A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
CA2935960C (fr) 2014-01-08 2023-01-10 Bart Lipkens Dispositif d'acoustophorese avec double chambre acoustophoretique
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CA2963820A1 (fr) 2014-11-07 2016-05-12 Editas Medicine, Inc. Procedes pour ameliorer l'edition genomique mediee par crispr/cas
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017053879A1 (fr) 2015-09-24 2017-03-30 Editas Medicine, Inc. Utilisation d'exonucléases pour améliorer l'édition de génome à médiation par crispr/cas
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3433363A1 (fr) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systèmes d'édition de génome comprenant des molécules d'enzyme modulant la réparation et leurs procédés d'utilisation
WO2017180694A1 (fr) 2016-04-13 2017-10-19 Editas Medicine, Inc. Systèmes d'édition de gènes de molécules de fusion cas9 et leurs procédés d'utilisation
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
ES2938210T3 (es) 2016-07-13 2023-04-05 Vertex Pharma Métodos, composiciones y kits para aumentar la eficiencia de edición del genoma
KR102632028B1 (ko) 2017-05-18 2024-01-31 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 페닐 유도체
EP3625223B1 (fr) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine
WO2018210987A1 (fr) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Dérivés de benzofurane et de benzothiophène utilisés en tant que modulateurs du récepteur pge2
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
WO2019014564A1 (fr) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systèmes et procédés d'intégration ciblée et d'édition du génome et détection de celle-ci à l'aide de sites d'amorçage intégrés
EP3725092A4 (fr) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. Circuit d'excitation et circuit de commande de transducteur acoustique
AU2019209290B2 (en) * 2018-01-17 2024-03-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
KR20200110685A (ko) 2018-01-17 2020-09-24 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
MA51623A (fr) 2018-01-17 2021-04-14 Vertex Pharma Composés de quinoxalinone, compositions, procédés et kits pour augmenter l'efficacité d'édition du génome
AU2019266240A1 (en) * 2018-05-07 2021-01-07 President And Fellows Of Harvard College Cell populations and gene expression associated with in vitro beta cell differentiation
US11833225B2 (en) 2018-05-24 2023-12-05 Crispr Therapeutics Ag Methods and compositions for efficient gene deletion
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
CN108949830B (zh) * 2018-08-03 2021-11-26 福州大学 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法
EP3640329A1 (fr) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Traitement du cancer à base d'édition de gène
US11473124B2 (en) 2018-12-12 2022-10-18 Depixus Method of nucleic acid enrichment using site-specific nucleases followed by capture
WO2020205664A1 (fr) * 2019-03-29 2020-10-08 Youhealth Biotech, Limited Compositions et méthodes de reprogrammation cellulaire pour sauver la fonction visuelle
WO2020227255A1 (fr) * 2019-05-06 2020-11-12 The Regents Of The University Of Michigan Thérapie ciblée
TW202118873A (zh) 2019-08-27 2021-05-16 美商維泰克斯製藥公司 用於治療與重複性dna有關之病症之組合物及方法
CN112553330B (zh) * 2019-09-26 2022-07-26 首都医科大学附属北京友谊医院 新型肿瘤相关转录因子zscan16及其在抑制肿瘤中的应用
US20220340936A1 (en) * 2019-09-27 2022-10-27 The Broad Institute, Inc. Programmable polynucleotide editors for enhanced homologous recombination
US20210130828A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Gin recombinase variants
CN110863011A (zh) * 2019-11-28 2020-03-06 浙江大学 干扰猪crtc3表达的质粒及腺病毒的构建方法及其用途
CN112877364B (zh) * 2019-11-29 2023-07-28 中国医学科学院药物研究所 软骨下骨细胞向关节软骨细胞直接转化的重编程诱导方案
CN111088290B (zh) * 2019-12-30 2021-10-08 同济大学 一种杜鹃素在基因编辑中的应用
CN115397811B (zh) 2020-01-20 2025-05-23 奈奥芬莱有限公司 与atp结合位点结合的异吲哚啉衍生物
JP7649562B2 (ja) * 2020-02-19 2025-03-21 国立大学法人京都大学 ゲノム編集された細胞の製造方法及びそのためのキット
WO2021234389A1 (fr) * 2020-05-21 2021-11-25 Oxford Genetics Limited Amplificateurs hdr
GB202008201D0 (en) * 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
CN113897357A (zh) * 2020-07-06 2022-01-07 北京大学 Twist1基因编辑系统及其在制备治疗三阴性乳腺癌的产品中的应用
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
CN112750498B (zh) * 2020-12-30 2022-06-24 同济大学 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法
TW202302848A (zh) 2021-02-26 2023-01-16 美商維泰克斯製藥公司 以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
WO2022182959A1 (fr) 2021-02-26 2022-09-01 Vertex Pharmaceuticals Incorporated Compositions et méthodes pour le traitement de la dystrophie myotonique de type 1 avec crispr/slucas9
CN113373148B (zh) * 2021-06-16 2022-08-26 中国人民解放军军事科学院军事医学研究院 一种调控app表达的靶标位点序列及其在防治ad上的应用
WO2023018637A1 (fr) 2021-08-09 2023-02-16 Vertex Pharmaceuticals Incorporated Édition génique d'éléments régulateurs
KR20240134108A (ko) * 2021-10-29 2024-09-06 듀크 유니버시티 Rna-프로그램가능한 세포 편집을 위한 조성물 및 시스템 및 이의 제조 및 사용 방법
CN114277119B (zh) * 2021-12-09 2023-05-16 浙江大学医学院附属邵逸夫医院 一种环状RNA circ-Arsb在制备防治骨质疏松产品中的应用
CN118475693A (zh) * 2021-12-24 2024-08-09 国立大学法人大阪大学 利用了同源重组的基因组编辑细胞的制造方法
IL314578A (en) * 2022-02-01 2024-09-01 Brigham & Womens Hospital Inc Generation of brown adipocytes from human pluripotent stem cells
CN114685494B (zh) * 2022-03-16 2024-04-16 中国人民解放军军事科学院军事医学研究院 SpCas9抑制剂的合成制备方法及其应用
CN114524811B (zh) * 2022-03-16 2025-01-24 中国人民解放军军事科学院军事医学研究院 Lxh0307、lxh0308作为基因编辑的小分子抑制剂及其应用
CN116004542A (zh) * 2022-09-26 2023-04-25 苏州吉纳星辰生物技术有限公司 一种提高基因敲入效率的方法及其应用
CN116286975A (zh) * 2023-02-21 2023-06-23 浙江大学 一种基于dCas9的c-NHEJ定点抑制系统及应用
WO2024238691A2 (fr) * 2023-05-15 2024-11-21 The Regents Of The University Of California Système d'édition du gène adnp
WO2025024785A2 (fr) * 2023-07-26 2025-01-30 University Of Utah Research Foundation Compositions et procédés de régulation de znf865
CN119215053B (zh) * 2024-12-05 2025-04-01 南昌大学 Ye6144在制备治疗乳腺癌引起的骨骼肌萎缩药物中的应用
CN119752995B (zh) * 2024-12-26 2025-11-28 中国农业科学院棉花研究所 GhNFXL1基因在提高棉属植物耐盐性和/或耐冷性中的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789538A (en) 1904-11-11 1905-05-09 Colin E Ham Dumb-bell.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2181548C (fr) 1994-01-18 2009-11-03 Carlos F. Barbas, Iii Derives de proteine a doigts zinciques et procedes associes
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
WO1995025809A1 (fr) 1994-03-23 1995-09-28 Ohio University Acides nucleiques compactes et leur distribution aux cellules
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
ATE466952T1 (de) 1998-03-02 2010-05-15 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
DE60023936T2 (de) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
KR20020086508A (ko) 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2002336373A1 (en) 2001-08-20 2003-03-03 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
BRPI0307383B1 (pt) 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation método de recombinação genética direcionada em célula de planta hospedeira
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1737498A2 (fr) 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Traitement de la douleur neuropathique au moyen de proteines a doigts de zinc
AU2005232665B2 (en) 2004-04-08 2010-05-13 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
CA2615532C (fr) 2005-07-26 2016-06-28 Sangamo Biosciences, Inc. Integration et expression ciblees de sequences d'acides nucleiques exogenes
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
CN101855231B (zh) 2007-06-19 2014-06-11 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗-反向硫代磷酸类似物的合成和用途
EP2315829B1 (fr) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Cellules souches pluripotentes induites
PT2534173T (pt) 2010-02-08 2019-10-31 Sangamo Therapeutics Inc Semidomínios de clivagem manipulados
MX374399B (es) 2012-02-29 2025-03-06 Sangamo Biosciences Inc Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
SI2841428T1 (sl) * 2012-04-24 2018-12-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
EP3494997B1 (fr) 2012-07-25 2019-09-18 The Broad Institute, Inc. Protéines de liaison à l'adn inductibles, outils de perturbation du génome et leurs applications
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
KR102315098B1 (ko) 2012-11-01 2021-10-21 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
CN113528577B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
EP3825401A1 (fr) 2012-12-12 2021-05-26 The Broad Institute, Inc. Systèmes de composants crispr-cas, procédés et compositions pour la manipulation de séquence
WO2014093709A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
EP2932421A1 (fr) 2012-12-12 2015-10-21 The Broad Institute, Inc. Procédés, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
EP2931899A1 (fr) 2012-12-12 2015-10-21 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
IL300461A (en) 2012-12-12 2023-04-01 Harvard College Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
CN110540991B (zh) * 2013-03-15 2023-10-24 通用医疗公司 使用截短的引导RNA(tru-gRNA)提高RNA引导的基因组编辑的特异性
WO2014172458A1 (fr) 2013-04-16 2014-10-23 University Of Washington Through Its Center For Commercialization Activation d'une autre voie pour la réparation dirigée par homologie afin de stimuler la correction génétique et le génie génomique
EP3825406A1 (fr) 2013-06-17 2021-05-26 The Broad Institute Inc. Administration et utilisation de systèmes crispr-cas, vecteurs et compositions pour le ciblage et le traitement du foie
EP3011035B1 (fr) 2013-06-17 2020-05-13 The Broad Institute, Inc. Test pour l'évaluation quantitative du clivage de sites cibles par une ou plusieurs séquences guides du système crispr-cas
EP3011033B1 (fr) 2013-06-17 2020-02-19 The Broad Institute, Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, procédés de composition, cribles et applications de ces derniers
AU2014281031B2 (en) 2013-06-17 2020-05-21 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
KR20160044457A (ko) 2013-06-17 2016-04-25 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 탠덤 안내 시스템, 방법 및 조성물의 전달, 조작 및 최적화
KR20160034901A (ko) 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
KR101448678B1 (ko) 2013-08-12 2014-10-08 김형기 단추 재봉실의 뿌리감기 장치
US20150095137A1 (en) 2013-09-27 2015-04-02 Stout Partners LP System and apparatus for effective coordination and scheduling of accesses to rate limited online sites to obtain data for use in assessing social metrics based on domain tailored evaluation of social media exposure
US20160237455A1 (en) 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
PT3424920T (pt) 2013-10-17 2020-07-07 Vertex Pharma Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
ES2780904T3 (es) 2014-08-17 2020-08-27 Broad Inst Inc Edición genómica usando nickasas Cas9
ES3013183T3 (en) 2014-11-21 2025-04-11 Regeneron Pharma Methods for targeted genetic modification using paired guide rnas
ES2938210T3 (es) 2016-07-13 2023-04-05 Vertex Pharma Métodos, composiciones y kits para aumentar la eficiencia de edición del genoma

Also Published As

Publication number Publication date
AU2021232813A1 (en) 2021-10-14
CN109863143A (zh) 2019-06-07
WO2018013840A1 (fr) 2018-01-18
EP3484870B1 (fr) 2022-11-16
AU2017295720B2 (en) 2021-07-22
EP4219462A1 (fr) 2023-08-02
EP3484870A1 (fr) 2019-05-22
US20220106615A1 (en) 2022-04-07
US12031150B2 (en) 2024-07-09
CN109863143B (zh) 2021-10-15
ES2938210T3 (es) 2023-04-05
US11124805B2 (en) 2021-09-21
AU2021232813B2 (en) 2023-04-13
US20190225990A1 (en) 2019-07-25
AU2017295720A1 (en) 2019-02-07
CA3030783A1 (fr) 2018-01-18
JP2019521139A (ja) 2019-07-25
JP7033583B2 (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
MA45670A (fr) Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
EP3500271A4 (fr) Activateurs d'édition du génome
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
MA51623A (fr) Composés de quinoxalinone, compositions, procédés et kits pour augmenter l'efficacité d'édition du génome
IL269887A (en) Compounds for increasing genome editing efficiency
EP3864152A4 (fr) Procédés et compositions pour éditer des arn
MA41253A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr
EP3507379A4 (fr) Procédés d'amplification numérique du génome entier
MA45397A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr
EP3386550A4 (fr) Procédés et compositions pour la fabrication et l'utilisation d'acides nucléiques de guidage
EP3485023C0 (fr) Procédés et compositions pour l'édition de génome dans des cellules non divisibles
EP3359523A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3436581A4 (fr) Procédés d'amplification de transcriptome entier
EP3546575A4 (fr) Procédé d'édition du génome
EP3331571A4 (fr) Compositions et procédés pour traiter des infections virales
EP2959005A4 (fr) Composés, compositions, procédés, et kits liés à l'extension de télomères
WO2017064566A3 (fr) Modification inductible d'un génome cellulaire
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3325669A4 (fr) Compositions et procédés d'analyse d'arn
EP3322679A4 (fr) Procédés et compositions pour améliorer les caractéristiques d'une plante
EP3370741A4 (fr) Procédés et compositions pour l'édition de gènes dans des cellules souches hématopoïétiques
FR3015187B1 (fr) Utilisation d'une composition renfermant du 1,3-propanediol comme e-liquide
EP3490366A4 (fr) Procédés et compositions pour l'expression de gènes dans des plantes
MA42488A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr